Hormonal
Extending the dosing interval of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) from once-weekly to once-every-two-weeks maintains approximately 70-75% of the weight loss efficacy while reducing total drug cost by 50%.
If you are taking a GLP-1 drug like semaglutide or tirzepatide, ask your doctor about extending your dosing interval to every two weeks. Mathematical models suggest this could cut your medication costs by 50% while keeping about 75% of the weight loss benefits. This is not a substitute for medical advice, but it is a potential strategy to improve affordability and adherence.
Reducing dose frequency does not commensurately reduce weight loss. For example, merely switching from one dose per week (q1wk) to one dose every two weeks (q2wk) maintains roughly 75% of the weight loss.
Why this rating
The evidence is derived from mathematical modeling and simulation, not a randomized controlled trial of the specific alternative regimen.
Source
Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy
Anıl Cengiz et al. · medRxiv · 2024
DOI 10.1101/2024.11.27.24318093
More from this paper
- For patients on lower doses of tirzepatide (e.g., 5 mg), switching to a less frequent dosing schedule (e.g., every two weeks) while simultaneously increasing the dose size (e.g., to 10 mg or 15 mg) can maintain or even exceed the weight loss efficacy of the standard once-weekly regimen.Limited
- At a population level, distributing GLP-1 medications using less frequent dosing regimens (e.g., every two weeks) allows twice as many obese adults to be treated with the same total drug supply, leading to greater reductions in national obesity rates and mortality compared to standard once-weekly dosing.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →